Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. Carl L. Hansen

Market Cap

2.13 Billion USD

Sector

Healthcare

Website

https://www.abcellera.com

Description

AbCellera Biologics Inc.

Read More

Overview

Value

48

Growth

52

Health

72

Management

16

Analyst Opinion

69

Total

51

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low risk of bankruptcy
  • Has strong financial health
  • Price-to-earnings ratio of 13.3 is lower than the market average (19.6x)
  • Low preportion of income is paid as dividend

Risk Factors

  • Earnings are negative
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • 0

Market Peers

ABCL

Key Figures

PE Ratio (TTM)

13.34

Margin Of Safety (DCF)

-16.30%

Revenue Growth (5 Year Average)

21.08%

Ratings Consensus

Buy

Share Buybacks

-2.37%

Dividend Yeild (TTM)

N/A

Valuation

Value Score

48

  • Price-to-earnings ratio of 13.3 is lower than the market average (19.6x)
  • Free-cashflow-yeild of 9.61% is better than the market average (4.7%)
  • Estimated intrinsic-value of 6.20 USD is lower than current price ( 7.42 USD)
  • Margin-of-safety of -16.30% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 5.4 USD

Current Price: 7.4 USD

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

13.34x

Free Cashflow Yeild

9.61%

PE/Earnings Growth

N/A

Price/Book

1.73x

Growth

Growth Score

52

  • 5 Year Average Revenue growth of 21.08% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 14.83% is higher than the market average (12.35%)
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • Free Cashflow growth has slowed this year

Revenue Growth

21.08%

Earnings Growth

N/A

Cashflow Growth

14.83%

Health

Health Score

72

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Debt repayments do not significantly impact cashflow

Altman Z Score

6.16

Piostroski Score

6.00

Debt/Equity

0.07x

Current Assets/Liabilities

8.67x

Free Cashflow/Total Debt

0.23x

Debt/Capital

0.08x

Management

Management Score

16

  • Has issued new shares to finance growth when share price is high
  • Return-on-capital-employed of -0.04% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of -2.44% is lower than the market average (15%)

Average Buybacks/Dilution

-2.37%

Recent Buybacks/Dilution

0.83%

5 Year Price Volitility

62.49%

Return On Assets

-1.96%

Return On Capital Employed

-0.04%

Return On Equity

-2.44%

Return On Free Cashflow

21.33%

Return On Investments

-5.27%

Analysts

Analyst Opinion

69

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

AbCellera Biologics Inc.

Currency

USD

Beta

-0.428002

Vol Avg

2041675

Ceo

Dr. Carl L. Hansen

Cik

0001703057

Cusip

Exchange

NASDAQ Global Select

Full Time Employees

475

Industry

Biotechnology

Sector

Healthcare

Ipo Date

2020-12-11

Address

2215 Yukon Street

City

Vancouver

State

BC

Country

CA

Zip

V5Y 0A1

Phone

604 559 9005

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies